This paper studies the licensing of a product innovation in a duopoly by means of two-part tariff contracts composed of fixed-fee payments combined with per-unit or ad-valorem royalties. When the licensor is a firm within the industry (internal licensor), it licenses the innovation to its competitor by using a pure ad-valorem royalty, and welfare is reduced because the royalty has anticompetitive effects on market performance. On welfare grounds, fixed-fee predominates over per-unit royalty licensing, but has the disadvantage that firms sometimes fail to reach an agreement. A simple regulatory rule is then proposed for a second-best optimal policy on product innovation licensing. However, when the innovator is outside the industry (external licensor), it never uses ad-valorem royalties. Also evaluated is the value of the innovation for an internal and an external innovator, and licensing by both innovators under Bertrand competition.
No takes yet. Share an insight, caveat, or question.
Antelo et al. (2023) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: